Neuralytix Expands iD3 System for Spine Surgery
Fruita, Colorado, August 12, 2026 Neuralytix, LLC announced the full commercial availability of its iD3 System, an FDA 510(k)-cleared...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Fruita, Colorado, August 12, 2026 Neuralytix, LLC announced the full commercial availability of its iD3 System, an FDA 510(k)-cleared...
BURLINGTON, Mass., August 12, 2026 Bone Biologics Corporation announced that its rhNELL-1 protein has achieved a validated shelf life...
NEW YORK, July 29, 2026 VB Spine LLC announced that the U.S. Food and Drug Administration (FDA) has granted...
LOUISVILLE, Colo., July 21, 2026 Synergy Spine Solutions has announced a major commercial milestone for its FDA-approved Synergy Disc®,...
Westminster, Colo., Jan. 13, 2026 — Cerapedics Inc. announced that the U.S. Food and Drug Administration (FDA) has approved...
ALTSTÄTTEN, Switzerland & BOSTON, November 14, 2025 — icotec Medical has received U.S. FDA clearance for its CMORE® CT...
